

C-2 Desmethyl Seco-Mevinic Acids. Monocyclic HMG-CoA Reductase Inhibitors


Dinesh V. Patel* and Eric M. Gordon

Bristol-Myers Squibb Pharmaceutical Research Institute
 P.O. Box 4000, Princeton, NJ 08543-4000

(Received 22 August 1991)

Abstract: An efficient preparation of C-2 desmethyl seco-mevinic acid **2a** from 2-cyclohexen-1-one (10 steps, 24.7% overall yield) is described. Comparison of the activity of analogs **2a,b** with other recently reported seco-mevinic acid based HMG-CoA reductase inhibitors suggests that all four substituents around the cyclohexyl ring are required for good biological activity.

HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors like pravastatin and lovastatin have recently attracted a great deal of medical attention as cholesterol lowering agents.¹ In our research program directed towards the preparation of potent and selective inhibitors of this enzyme, seco-mevinic acid **1** was recently identified as a novel lead ($IC_{50} = 8$ nM).² Unfortunately, the high level of synthetic complexity associated with the preparation of enzyme inhibitors like **1** hindered their rapid exploitation. This prompted us to design a short and practical synthesis of the desmethyl analog **2a**, which if active, would offer greater synthetic flexibility in terms of exploring this new structural class of inhibitors. Herein, we report the synthesis of seco-mevinic acid **2a** and its unsaturated analog **2b**, and by comparing their *in vitro* potency with related seco analogs **3**³ and **4**^{4,5}, propose the minimal structural requirements for potent, seco-mevinic acid based HMG-CoA reductase inhibitors.




Seco-mevinic acids **2a,b** possess three contiguous chiral centers around the cyclohexane ring, which in turn bear a 1,2-*trans* relationship relative to each other. The most appealing synthetic strategy involved preparation of aldehyde **10a** and its reaction with the β -ketophosphonate **11**.⁶ Since all three substituents in aldehyde **10a** are equatorial, we envisioned preparing this thermodynamic isomer by Wittig homologation of ketone **6** or **8** followed by epimerization under equilibrating conditions. We planned to secure the 1,2-*trans* relationship in ketone **6** by 1,4-cuprate type addition to cyclohexenone.

Selective 1,4-addition of the *n*-propyl group to 2-cyclohexen-1-one required considerable experimentation. The copper catalyzed *n*-propyl Grignard addition proceeded better in ether than in THF. Superior yields were realized when the enolate was trapped with TMSCl (88%), instead of performing a direct hydrolytic quench (66%). This highlights the role of chlorotrimethylsilane in enhancing the rate and selectivity of 1,4-addition reactions.⁷ While the lithium enolate generated from the silyl enol ether **5** failed to react with benzyl chloromethyl ether (BOM-Cl) even in the presence of HMPA or upon addition of NaI, it reacted efficiently with benzyl bromomethyl ether (BOM-Br) to provide the β -benzyloxy ketone **6** in high yields. This was a sensitive reaction which gave slightly variable yields (85-94%), but more importantly, its stereoselectivity (>19:1 to 5:1) was critically dependent on the reaction temperature and the quality of the BOM-Br reagent.⁸ Although the minor *cis* epimer could not be removed at this stage, the desired *trans* stereochemistry of the predominant diastereomer **6** was confirmed by ¹H NMR ($J_{\text{Ha-Hb}} = 10.1$ Hz). Debenzoylation of **6** provided the β -hydroxy ketone **7** and at this stage, its epimeric contaminant was readily removed by flash chromatography. Acylation of **7** to the ester **8** was straightforward. In the key event, Wittig homologation of ketone **8** and acidic hydrolysis of the intermediate enol ether **9** worked extremely well to provide the desired aldehyde **10ab** as a separable mixture of epimers in 80% overall yield (73% yield of desired epimer **10a** from **8**).⁹ Condensation of racemic aldehyde **10a** with the chiral β -keto phosphonate **11**⁶ (LiCl, DBU, CH₃CN)¹⁰ afforded the desired enone **12** in 59% isolated yield (90% conversion), which was accompanied by about 5% of undesired epimer.¹¹ This reaction thus permitted assembly of entire carbon framework of the final target molecule. In an attempt to minimize epimerization, milder conditions recently highlighted by Heathcock (LiBr, Et₃N, CH₃CN) were employed,⁴ however, some epimerization was still observed and the yields and conversion rates proved slightly inferior (32% isolated yield, 56% conversion, 5% epimerization). Attempted selective 1,4-reduction of the α,β -unsaturated ketone **12** ((Ph₃P)₃RhCl, PhMe₂SiH, C₆H₆)¹² followed by hydrolysis with aqueous hydrofluoric acid gave the desired ketone **13**, along with some related inseparable enone, signifying incomplete reaction during the hydrosilylation step. Alternatively cleavage of the silyl ether group from **12** followed by hydrogenation in ethyl acetate gave **13** in excellent yields. Selective *syn* reduction of the β -hydroxy ketone **13** followed well preceded literature conditions¹³ and gave the desired 1,3-diol which, upon hydrolysis with lithium hydroxide and purification by HP20 column chromatography afforded **2a** as the lithium salt. This completed our preparation of the seco-mevinic acid **2a** from 2-cyclohexen-1-one in 10 steps and 24.7% overall yield. Alternatively, desilylation of **12**, followed by reduction and hydrolysis provided the unsaturated analog **2b**.

The C-2 desmethyl analog **2a** was found to be 212 fold less active as an HMGR inhibitor than the parent compound **1** (see Table). If one of the diastereomers in **2a** is assumed to be inactive,^{11a} it still reflects a loss of two orders of magnitude in activity. This suggests that the two substituents on the cyclohexyl ring system that flank the diol acid side chain might be serving to orient it in the right conformation for optimal binding and/or the

Scheme I



a) $n\text{-PrMgCl}$, $\text{CuBr}\cdot\text{Me}_2\text{S}$, Et_2O ; TMSCl , Et_3N , HMPA (88%) b) MeLi , THF , r.t., 45 min.; BOMBr , -78° to r.t. (85-94%) c) H_2 , $\text{Pd}(\text{OH})_2/\text{C}$ (75%) d) $\text{EtC}(\text{Me})_2\text{C}(\text{O})\text{Cl}$, Pyridine , DMAP (95%) e) $n\text{BuLi}$, $\text{Ph}_3\text{P}^+\text{CH}_2\text{OMe Cl}^-$ 4:1 $\text{Et}_2\text{O}/35\% \text{HClO}_4$, r.t., 14 h (73% **8a** from **6**) f) LiCl , DBU , CH_3CN , r.t., 48 h, (90% conversion, 59% isolated yield) g) 48% aq. HF , CH_3CN (86%) h) H_2 , 10% Pd/C , EtOAc (94%) i) Et_3B , $t\text{BuCO}_2\text{H}$; NaBH_4 , MeOH ; H_2O_2 (84% for **2a**, 75% for **2b**) k) 1N LiOH , dioxane (quant.)

C-2 methyl group is involved in important hydrophobic interactions. While the impressive *in vitro* potency of seco-mevinic acid **1** indicates that conformational restriction of the butyrate ester side chain is not necessary, the inactivity of despropyl analog **3**³ clearly illustrates the critical requirement of an *n*-propyl group. The two desalkyl analogs **2a** and **3** involve complementary deletions on the parent acid **1**. However, other structural differences between them precludes a direct assessment of the relative significance of the C-2 vs. C-5 substituents. As expected, further simplification of this class of compounds, represented by **4a**⁴ and **4b**⁵, has also been found to be ineffective. In conclusion, the results on analogs 2-4 summarized in this communication lead us to hypothesize that in the monocyclic seco-mevinic acid series, all the four substituents around the cyclohexyl ring are required for efficient binding to and inhibition of HMGR.

Acknowledgements :

We wish to thank Dr. Carl P. Ciosek for testing of compounds **2a** and **2b**, and Dr. D. S. Karanewsky for helpful discussions during the progress of this work.

Notes and References :

- 1 Roth, B. D.; Sliskovic, D. R.; Trivedi, B. K.: *Annual reports in Medicinal Chemistry*; Allen, R. C. Ed.; Academic Press, Inc.: San Diego, CA, **1989**, *24*, pp. 147-156.
- 2 Karanewsky, D. S. *Tetrahedron Lett.* **1991**, *32*, 3911.
- 3 Damon, R. E.; Coppola, G. M.; Vedananda, T. *200th National ACS Meeting*, August 26-31, 1990, Washington, DC.
- 4 Compound **4a**: Heathcock, C. H.; Davis, B. R.; Hadley, C. R. *J. Med. Chem.* **1989**, *32*, 197.
- 5 Compound **4b** was prepared by Dr. David R. Magnin at Bristol-Myers Squibb (unpublished results).
- 6 a) Theisen, P. D.; Heathcock, C. H. *J. Org. Chem.* **1988**, *53*, 2374. b) Karanewsky, D. S.; Malley, M. F.; Gougoutas, J. Z. *J. Org. Chem.* **1991**, *56*, 3744.
- 7 a) Matsuzawa, S.; Horiguchi, Y.; Makamura, E.; Kuwajima, I. *Tetrahedron* **1989**, *45*, 349. b) Bergdahl, M.; Lindstedt, E.-L.; Nilsson, M.; Olsson, T. *Tetrahedron* **1989**, *45*, 535. c) Johnson, C. R.; Marren, T. J. *Tetrahedron Lett.* **1987**, *28*, 27.
- 8 Utilization of freshly prepared BOM-Br obtained by treatment of benzyl chloromethyl ether (Aldrich) with anhydrous HBr in dichloromethane at 0°C gave highest selectivity.
- 9 a) Interestingly, whereas hydrolysis of the enol ether **9** with 4:1 ether/35% perchloric acid initially (1 h) afforded a mixture of two epimers, prolonged treatment under the same conditions (overnight stirring, 12 h) yielded predominantly the slow moving isomer **10a**. TLC: (9:1 hexane/ethylacetate) $R_f = 0.24$ for **10a** and 0.28 for epimer **10b**.
b) The α -proton of the major aldehyde **10a** was shifted upfield and appeared as a broad multiplet with two large diaxial couplings (2.3 ppm, $J = 10.7, 11.3, 3.6$ ppm) compared to that of the minor epimer **10b** (2.65 ppm, narrow multiplet) suggesting the axial and equatorial positions of the α -protons of **10a** and **10b** respectively. Additionally, the aldehyde proton of the major epimer **10a** was shifted upfield compared to that of the minor epimer **10b** (9.58 ppm vs. 9.77 ppm), which conforms the trend of equatorial aldehyde proton appearing upfield relative to the axial aldehyde.
c) The epimeric impurity (approx. 5%) was readily removed in the next step upon desilylation of **12**.
- 10 a) Rathke, M. W.; Nowak, M. *J. Org. Chem.* **1985**, *50*, 2624. b) Blanchette, M. A.; Choy, W.; Davis, J. T.; Essendorf, A. P.; Masamune, S.; Roush, W. R.; Sakai, T. *Tetrahedron Lett.* **1984**, *25*, 2183.
- 11 a) In compound **12**, stereochemistry around the cyclohexyl ring is relative and not absolute, since it is actually an inseparable mixture of two diastereomers obtained by reaction of racemic aldehyde **10a** with the homochiral β -ketophosphonate **11**. Thus, the final target molecules **2a** and **2b** are mixtures of two diastereomers.
b) The relative all equatorial stereochemistry of the the substituents around the cyclohexyl ring system was once again confirmed by the fact that the allylic H_c proton of the major isomer **12** appeared as a broad multiplet, revealing axial-axial couplings, and was shifted upfield (2.2 vs. 2.7 ppm) compared to the narrow multiplet of the allylic proton of the minor epimer of **12**.
c) The epimeric impurity (approx. 5%) was readily removed in the next step upon desilylation of **12**.
- 12 a) Ojima, I.; Kogure, T.; Nagai, Y. *Tetrahedron Lett.* **1972**, *49*, 5035. b) Ojima, I.; Nihonyanagi, M.; Kogure, T.; Kumagai, M.; Horiuchi, S.; Nakatsuguma, K. *J. Organometal. Chem.* **1975**, *94*, 449.
- 13 a) Narasaka, K.; Pai, F.-C. *Tetrahedron* **1984**, *40*, 2233. b) Kathawala, F. G.; Prager, B.; Prasad, K.; Repic, O.; Shapiro, M. J.; Stabler, R. S.; Widler, L. *Helv. Chim. Acta.* **1986**, *69*, 803.